Showing 2891-2900 of 7670 results for "".
- Skin Bleaching for a Lighter Complexion Carries Serious Riskshttps://practicaldermatology.com/news/skin-bleaching-for-a-lighter-complexion-carries-serious-risks/2460769/Despite the potential dangers of skin bleaching products, the global market for skin lighteners last year was estimated at $8.6 billion and is projected to reach $12.3 billion by 2027. “The cultural beliefs that promote the practice of skin bleaching date back centuries and deeply affect many of …
- Visible Light from the Sun Causes Pigmentary Skin Changeshttps://practicaldermatology.com/news/visible-light-from-the-sun-causes-pigmentary-skin-changes/2460768/Visible light from the sun plays a significant role in causing pigmentary skin changes, particularly in people with skin of color, according to information presented at AAD VMX 2021. “We know from decades of research that unprotected exposure to ultraviolet light from the sun can lead to skin canc…
- Leo Pharma’s Tralokinumab Produces Sustained Improvement in ADhttps://practicaldermatology.com/news/leo-pharmas-tralokinumab-produces-sustained-improvement-in-ad/2460766/Leo Pharma’s tralokinumab 300 mg every other week plus optional topical corticosteroids (TCS) showed long-term improvements in itch, sleep, and in atopic dermatitis signs and symptoms, according to an interim analysis at 56 weeks in the ECZTEND trial that was presented at the AAD 2021 VMX. Traloki…
- UCB’s Bimekizumab Outplays the Competition in Two Phase 3 Psoriasis Trialshttps://practicaldermatology.com/news/ucbs-bimekizumab-outplays-the-competition-in-two-phase-3-psoriasis-trials/2460764/UCB’s Bimekizumab almost entirely cleared moderate to severe psoriasis in more than 60 percent of the patients who took part in two Phase 3 clinical trials. Given via injection under the skin, Bimekizumab is a monoclonal antibody and the first to block both Interleukin 17A and Interleukin 17F whic…
- Phase 3 Data Show Tolerability, Efficacy for Brickell's Sofpironium Bromide in Hyperhidrosishttps://practicaldermatology.com/news/phase-3-data-show-tolerability-efficacy-for-brickells-sofpironium-bromide-in-hyperhidrosis/2460763/Data from the phase 3, open-label, long-term safety study of Brickell Biotech’s sofpironium bromide gel, 5% and 15%, provided clinically meaningful improvement in axillary hyperhidrosis severity as measured by the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax), a proprietary patient-repo…
- Biosimilar News: Switching Study Shows Cyltezo and Humira Are Interchangeablehttps://practicaldermatology.com/news/biosimilar-news-switching-study-shows-cyltezo-and-humira-are-interchangeable/2460762/Switching between adalimumab biosimilar Cyltezo and its reference product results in similar pharmacokinetics, efficacy, safety and immunogenicity in people with moderate-to-severe chronic plaque psoriasis, according to new Phase 3 data presented at the American Academy of Dermatology 2021 virtual …
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly selective, once-daily, …
- Zoom Dysmorphia Fuels Boost in Cosmetic Consultshttps://practicaldermatology.com/news/zoom-dysmorphia-fuels-boost-in-cosmetic-consults/2460760/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified dermatologis…
- Favorable 5-Year Data for Janssen’s Tremfya in PsOhttps://practicaldermatology.com/news/favorable-5-year-data-for-janssens-tremfya-in-pso/2460758/Newly presented phase 3 data show that Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years. Treatment improved disease activity…
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study assessed response to dupilumab treatment using a combination of signs (EASI-50…